I can't resist pointing out how exciting it is that virtually every vaccine in the world has Canadian research based in it. Certainly when you look at the lipid nanoparticle technology that is centred in British Columbia with Dr. Pieter Cullis and others, it's very exciting for all of us in the field to see that technology coming to the fore in vaccines—for virtually every vaccine in the world. I think we've seen other manufacturing advances that are quite helpful as well.
There is a lot more work to do. We would be making a mistake to rest on this progress. We need to make sure that we continue to build the manufacturing infrastructure and continue to build the industry.
Again, relative to the work of this committee, I am really interested in encouraging public policy-makers to focus on the talent that we need to respond to those jobs. We've seen from third party measures, like the BioTalent study that I referenced, that there is a significant opportunity for the attraction and growth of talent in this space. We need to make sure that we continue to support that effort.